Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2023-11-01 00:00:00 ET · period of report 2023-10-30 · accession 0001415889-23-014680 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-01 | 2023-10-30 | TBPH | GRAHAM RICHARD A | SVP, RESEARCH, DEVELOPMENT | A - Grant | $0.00 | +15.0K | 349.3K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-10-30 | A | A | 15,000 | $0.00 | 349,321 | D | — | — | (F1) On March 1, 2023 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of a performance condition by December 31, 2023 and continued employment. On October 30, 2023 the performance conditions were achieved. As a result 50% of the restricted stock units will vest on November 20, 2023 and the remaining 50% of the restricted stock units will vest on November 20, 2024, subject to the reporting person's continued service. |